Across the world, nearly one in five people carries an inherited cardiovascular risk factor they will likely never know about — not because the knowledge is unavailable, but because the systems meant to protect them have not yet made room for it. Lipoprotein(a), or Lp(a), is written into a person's genetic code before childhood and cannot be altered by diet or discipline, yet fewer than one in fourteen people in Asia Pacific and the Middle East have ever been tested. On the eve of World Heart Day 2025, global health experts gathered to name this silence for what it is: not a failure of individ
The Manila Times
· Sep 24, 2025
· health
· 8 min de leitura
Medium
Apuração: Caracterizado
1 in 5 People Face Hidden Genetic Heart Disease Risk, Experts Warn of Lp(a) Testing Gap
Cardiovascular disease kills nearly 18 million people annually worldwide, with elevated Lp(a) as a significant unrecognized risk factor contributing to heart attacks and strokes.
◉
Politics & Governance
18579 artigos relacionados
Burnham to convene UK nations summit in October push for 'good jobs'
BBC News · 100% correspondência
Paxton defeats Cornyn in Texas Senate primary, reshaping GOP landscape
BBC News · 99% correspondência
Senate breaks ranks to rebuke Trump's Iran war with historic War Power…
The Hindu · 99% correspondência
Senate Approves Iran War Powers Resolution in Historic Rebuke to Trump
The Times of Israel · 99% correspondência
Senate Approves War Powers Resolution Against Iran Conflict in Histori…
Japan Today · 99% correspondência
Cobertura Relacionada
The Guardian · Sep 23
Burnham seeks diplomatic balance as UK navigates Trump's reshuffled world order
UK PM Andy Burnham meets Donald Trump at the UN, seeking to balance diplomatic relations while maintaining principled st…
NPR · Sep 23 Trump administration to remove 760,000 ACA enrollees over fraud allegationsThe Trump administration plans to remove 760,000 Affordable Care Act enrollees, claiming fraudulent enrollment or non-ex…
The Guardian · Sep 23 Victoria's Big Build inquiry reveals early warnings of bikies, criminals on state projectsVictoria's royal commission into Big Build infrastructure projects opens public hearings, revealing Premier Jacinta Alla…
The New York Times · Sep 23 White House Defends Trump's Media Outlet Bans in Court FilingThe Trump White House defended its ban of CNN, MS NOW, and Politico in court filings, citing violations of professional …
Viés e Enquadramento
⚖
Article presents health awareness messaging on Lp(a) testing with promotional framing favoring expanded screening, sponsored by pharmaceutical company Novartis without clear disclosure of commercial interests.
Bias Direction
center-right
Confidence
HIGH
Problem-solution narrative combined with authority appeal and urgency framing. Uses dramatic statistics (18M deaths annually) and emotional language ('little a with big consequences') to establish problem severity, then positions expanded testing/policy integration as solution. Framed as public health advocacy rather than commercial promotion.
hidden genetic threat
little a with big consequences
critical, underrecognized
remains largely invisible
that has to change
vital role
equitable access
Cost-benefit analysis of universal Lp(a) screening vs. targeted screening approaches
Potential harms of expanded testing (false positives, anxiety, overtreatment)
Independent health organizations' recommendations on Lp(a) screening protocols
Perspectives from patients who may face barriers beyond awareness
Competing cardiovascular risk factors that may warrant prioritization
Disclosure of Novartis's commercial interest in expanded testing markets
Impacto Geopolítico
🌎
Public health awareness campaign on genetic cardiovascular disease risk; primarily a medical/public health issue with no direct geopolitical implications.
Escalation Risk
low
Confidence
HIGH
Asia Pacific
Middle East
Global
No significant power dynamics shifts. This is a health advocacy initiative by Global Heart Hub and Novartis to increase medical testing awareness. No state actors, alliances, or geopolitical influence involved.
Lente Econômica
📈
Elevated Lp(a) genetic condition affecting 20% of global population remains largely undetected, creating significant public health and healthcare cost burden requiring expanded diagnostic testing and policy integration.
Market Signal
bullish
Confidence
HIGH
Healthcare and Pharmaceuticals
Diagnostic Testing and Laboratory Services
Health Insurance
Medical Device Manufacturing
Public Health Systems
Consumers face unquantified cardiovascular disease risk due to testing gaps, potentially leading to preventable heart attacks and strokes. Expanded Lp(a) testing will increase healthcare costs for individuals and households, but early detection could reduce catastrophic medical expenses and mortality-related economic losses.
Governments and health authorities should integrate Lp(a) screening into national cardiovascular disease prevention strategies, potentially mandate insurance coverage for testing, establish clinical guidelines for risk stratification, and fund public awareness campaigns. Healthcare systems may need to allocate resources for expanded diagnostic capacity and specialist training.